Related Experiment Videos
Molecular model of the alpha(IIb)beta(3) integrin
Bradley P Feuston1, J Christopher Culberson, George D Hartman
1Departments of Molecular Systems and Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. bradley_feuston@merck.com
Journal of Medicinal Chemistry
|December 4, 2003
Summary
A new molecular model of alpha(IIb)beta(3) integrin was created using existing structures and computational methods. This model accurately predicts ligand binding interactions, aiding in drug design.
Area of Science:
- Structural biology
- Molecular modeling
- Integrin research
Background:
- Integrins are crucial cell surface receptors involved in cell adhesion and signaling.
- Alpha(IIb)beta(3) integrin plays a key role in platelet aggregation.
- Understanding integrin-ligand interactions is vital for developing targeted therapies.
Purpose of the Study:
- To develop a detailed molecular model of the alpha(IIb)beta(3) integrin.
- To elucidate the binding interactions of alpha(IIb)beta(3) with small molecule inhibitors.
- To provide a structural basis for rational drug design targeting alpha(IIb)beta(3).
Main Methods:
- Utilized crystal structure of alpha(v)beta(3) and homology modeling for alpha(IIb) subdomain.
- Employed docking of dual and selective inhibitors into putative binding sites.
- Integrated mutagenesis data and small ligand binding modeling to refine loop conformations.
Main Results:
- Developed a refined 3D model of the alpha(IIb)beta(3) integrin head region.
- Identified key residues (alpha(IIb):E117 and beta(3):R214) dominating ligand-protein interactions.
- Confirmed the role of an 'exosite' involving Y190 in binding, consistent with alpha(v)beta(3) models.
Conclusions:
- The developed molecular model of alpha(IIb)beta(3) is consistent with experimental data.
- The model accurately predicts ligand binding, offering insights into inhibitor design.
- This structural understanding facilitates the development of novel therapeutics targeting alpha(IIb)beta(3).